Lasa Supergenerics Share Price

Lasa Supergenerics Investment Rating

• Master Rating:

• Lasa Supergenerics has an operating revenue of Rs. 129.94 Cr. on a trailing 12-month basis. An annual revenue de-growth of -32% needs improvement, Pre-tax margin of -5% needs improvement, ROE of -3% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 38 which is a POOR score indicating inconsistency in earnings, a RS Rating of 32 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 151 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.